Literature DB >> 1644334

HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis.

H Zetterquist1, U Broomé, K Einarsson, O Olerup.   

Abstract

The familial predisposition to chronic inflammatory bowel disease and the increased concordance rate in monozygotic twins with Crohn's disease, suggest that genetic factors influence disease susceptibility. A 100% association with the supertypic HLA class II specificity DRw52a was recently described in white North American patients with primary sclerosing cholangitis, with or without concurrent ulcerative colitis. HLA class II alleles of the DR, DQ, and DP subregions were determined by genomic typing techniques in a large group of Swedish patients with ulcerative colitis or Crohn's disease as well as in a series of patients with primary sclerosing cholangitis. No statistically significant HLA class II association was observed in any of the investigated diseases or when the patients were subgrouped according to disease site or occurrence of extraintestinal manifestations, except an insignificant increase of the DRw17, DQw2 haplotype in patients with primary sclerosing cholangitis. The failure to confirm the well established DRw17 association in Swedish patients with sclerosing cholangitis probably represents a statistical type II error. Furthermore, this study did not verify the recently described strong DRw52a association in sclerosing cholangitis--52% of the patients were DRw52a positive compared with 28% of the controls (p less than 0.05, pc NS). This discrepancy was probably caused by different typing techniques. The DRw52a specificity was determined directly by hybridising HLA-DRB3 genes, group specifically amplified by the polymerase chain reaction, with an allele specific oligonucleotide probe, whereas in the previously mentioned study DRw52a was assigned by indirect serological criteria, which overestimate the frequency of this allele.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1644334      PMCID: PMC1379409          DOI: 10.1136/gut.33.7.942

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  34 in total

1.  Association of primary sclerosing cholangitis with HLA-DRw52a.

Authors:  E J Prochazka; P I Terasaki; M S Park; L I Goldstein; R W Busuttil
Journal:  N Engl J Med       Date:  1990-06-28       Impact factor: 91.245

2.  HLA-A and -B antigens in inflammatory bowel disease.

Authors:  I Biemond; W R Burnham; J D'Amaro; M J Langman
Journal:  Gut       Date:  1986-08       Impact factor: 23.059

3.  Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking.

Authors:  C Tysk; E Lindberg; G Järnerot; B Flodérus-Myrhed
Journal:  Gut       Date:  1988-07       Impact factor: 23.059

4.  HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus.

Authors:  J A Todd; J I Bell; H O McDevitt
Journal:  Nature       Date:  1987 Oct 15-21       Impact factor: 49.962

Review 5.  DNA-RFLP analysis and genotyping of HLA-DR and DQ antigens.

Authors:  J Bidwell
Journal:  Immunol Today       Date:  1988-01

6.  HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive.

Authors:  T Juji; M Satake; Y Honda; Y Doi
Journal:  Tissue Antigens       Date:  1984-11

7.  Familial Crohn's disease in multiple siblings: no linkage to the HLA system.

Authors:  J F Colombel; F Guillemot; A Van Gossum; F Dufossé; A Cortot; E Dupont; J C Paris
Journal:  Gastroenterol Clin Biol       Date:  1989 Aug-Sep

8.  HLA antigens and clinical manifestations in Crohn's disease.

Authors:  V Modena; A Amoroso; C Frattasio; A Pera; P Costantini; I Maiocco; V Ponti; C C Di Vittorio; G Verme; E S Curtoni
Journal:  Clin Exp Rheumatol       Date:  1988 Jul-Sep       Impact factor: 4.473

9.  Genetic markers in narcolepsy.

Authors:  N Langdon; K I Welsh; M van Dam; R W Vaughan; D Parkes
Journal:  Lancet       Date:  1984-11-24       Impact factor: 79.321

10.  Different amino acids at position 57 of the HLA-DQ beta chain associated with susceptibility and resistance to IgA deficiency.

Authors:  O Olerup; C I Smith; L Hammarström
Journal:  Nature       Date:  1990-09-20       Impact factor: 49.962

View more
  7 in total

1.  HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis.

Authors:  P C Stokkers; P H Reitsma; G N Tytgat; S J van Deventer
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

2.  Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies.

Authors:  Bing Xia; JBA Crusius; SGM Meuwissen; AS Pe?a
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

Review 3.  Association of primary sclerosing cholangitis and celiac disease: a case report and review of the literature.

Authors:  Abdullah M S Al-Osaimi; Carl L Berg
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

Review 4.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

Review 5.  Large-duct cholangiopathies: aetiology, diagnosis and treatment.

Authors:  Shyam Menon; Andrew Holt
Journal:  Frontline Gastroenterol       Date:  2019-01-04

6.  Analysis of MHC class II DP, DQ and DR alleles in Crohn's disease.

Authors:  A Cariappa; B Sands; D Forcione; D Finkelstein; D K Podolsky; S Pillai
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

7.  Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.

Authors:  U Broomé; R Olsson; L Lööf; G Bodemar; R Hultcrantz; A Danielsson; H Prytz; H Sandberg-Gertzén; S Wallerstedt; G Lindberg
Journal:  Gut       Date:  1996-04       Impact factor: 23.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.